Pipeline
Translating data, science and technology into therapy
Silthera develops programs focused on rare and ultra-rare genetic diseases, with a specific emphasis on autosomal dominant mutations, where clinical need is high and design precision is a decisive factor
Silthera develops programs focused on rare and ultra-rare genetic diseases, with a specific emphasis on autosomal dominant mutations, where clinical need is high and design precision is a decisive factor
Candidates drugs development stages
Silthera-001
Disease Area: Visceral myopathy type 1
Target: Mutated gene associated with smooth muscle dysfunction
Silthera-002
Disease Area: Visceral myopathy type 2
Target: Mutated gene associated with smooth muscle dysfunction
Silthera-003
Disease Area: Osteogenesis imperfecta
Target: Genetic bone disorders
Silthera-004
Disease Area: Undisclosed